Pharmaceutical Distoloza S.a. Pharmaceutical Import Profile — Peru (DGFT 2022–2026)

Name: Pharmaceutical Distoloza S.a. Pharmaceutical Import Records from India — 2 Products, $38.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharmaceutical Distoloza S.a. — Pharmaceutical Importer Profile (2026) | 2 Products, $38.0K Trade | TransData Nexus

Pharmaceutical Distoloza S.a.

Pharmaceutical Importer · Peru · Oncology Focus · $38.0K Total Trade · DGFT Verified

Pharmaceutical Distoloza S.a. is a pharmaceutical importer based in Peru with a total trade value of $38.0K across 2 products in 1 therapeutic categories. Based on 6 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Pharmaceutical Distoloza S.a. sources from 5 verified Indian suppliers, with United Biotech Private Limited accounting for 73.6% of imports.

Pharmaceutical Distoloza S.a. — Import Portfolio & Supplier Network

Pharmaceutical Distoloza S.a. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Pharmaceutical Distoloza S.a.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
United Biotech Private Limited	$260.0K	26	73.6%
Medilatina Farma	$48.3K	1	13.7%
Xl Laboratories Private Limited	$39.0K

What Formulations Does Pharmaceutical Distoloza S.a. Import?

Formulation	Value	Ships
Caspofungin 50 MG INJ partimyna-pd 50 MG powder for concentrate for solution for	$48.3K	1
(diosmin 450MG+hesperidin 50MG coated	$39.0K	4
Cyplersamex injectable solution 20 ui/ML	$32.9K	2
Sol-u-pred 500 methylprednisolone sodiumsuccinate for injection USP 500 MG (b.no.mpdl3d14 md.12/23 ed.	$21.0K	1
Sol-u-pred methylprednisolone 500MG	$20.9K	2
Unicristin 1 MG injection. vincristine sulfate injection USP 1.0 MG 1.0/ML. b.no.ucia5a1 md.01/25	$20.8K	1
Devialin 500 methylprednisolone sodium succinate for injection USP 500 MG bn.mpda5d1 md.01/2025	$19.9K	1
Sol-u-pred 500 methylprednisolone sodiumsuccinate for injection USP 500 MG bn.mpde4d4 md.05/24	$15.0K	1
Cyplersamex injecton vasopressin	$14.1K	1
Cyplersamex 20iu INJ vassopressin INJ	$14.1K	1
Cyplersamex injectable solution 20 ui/ML.(vasopressin injection USP 20 units/ML).(b.no.vpic4b1 md.03/24 ed.	$12.9K	1
Cyplersamex injectable solution 20 units/ML ( vasopressin injection USP 20 units/ML (b.n.vpil4b11 md.12/2024	$12.5K	1
Unicristin 1 MG injection.vincristin	$11.6K	1
Unicristin 1 MG injection vincristin	$10.0K	2
Cyplersamex injectable solution 20 ui/ML(vasopressin injection USP 20 units/ML)b.no.vpik3b11 md.11/2023	$9.0K	1

Pharmaceutical Distoloza S.a. imports 27 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vincristine	Oncology	$26.8K	3	1.3%	7
2	Vinblastine	Oncology	$11.2K	3	1.5%	7

Pharmaceutical Distoloza S.a. imports 2 pharmaceutical products across 1 categories into Peru totaling $38.0K.

Pharmaceutical Distoloza S.a. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Pharmaceutical Distoloza S.A. is a Peruvian pharmaceutical company established on July 1, 2009. Headquartered in Lima, the company operates in the Miscellaneous Nondurable Goods Merchant Wholesalers sector, focusing on the wholesale distribution of pharmaceutical products. The company's main office is located at Av. Almte. San Lorenzo 708, Of. A-b, Piso 3, Urb. Cedros De Villa, Chorrillos, Lima. (delrisco.com.pe)

Pharmaceutical Distoloza S.A. is registered as a Sociedad Anónima (S.A.), a common corporate structure in Peru. The company is listed in the Registro Nacional de Proveedores (RNP) as a supplier of goods and services, indicating its active role in the pharmaceutical supply chain. While specific details about its parent company are not publicly available, the company's operations suggest a focus on the import and distribution of pharmaceutical products within Peru.

2Distribution Network

Pharmaceutical Distoloza S.A. maintains a distribution network with multiple establishments across Peru. In addition to its main office in Lima, the company operates facilities in Chorrillos and Santa Anita, Lima. These locations enable the company to effectively manage logistics and supply chain operations, ensuring timely delivery of pharmaceutical products to various regions within the country.

3Industry Role

Pharmaceutical Distoloza S.A. functions primarily as a pharmaceutical importer and wholesaler in Peru. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from international suppliers, particularly from India. By distributing these products to local pharmacies, hospitals, and healthcare providers, Pharmaceutical Distoloza S.A. plays a crucial role in ensuring the availability of essential medications within the Peruvian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Pharmaceutical Distoloza S.a.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Pharmaceutical Distoloza S.A. demonstrates a high level of supplier concentration, with a significant portion of its imports sourced from a single supplier, United Biotech Private Limited. Between 2022 and 2026, the company imported approximately $260,000 worth of products from United Biotech, accounting for 73.6% of its total imports from India. This reliance on a single supplier may pose risks related to supply chain disruptions, such as production delays or quality control issues.

The remaining imports are diversified among other suppliers, including Medilatina Farma, XL Laboratories Private Limited, Novo Medi Sciences Private Limited, and Rescuers Life Sciences Limited. This diversification strategy helps mitigate potential risks associated with over-reliance on a single supplier, ensuring a more resilient supply chain.

2Supply Chain Resilience

Pharmaceutical Distoloza S.A.'s supply chain resilience is influenced by its sourcing strategy. The company's significant dependence on United Biotech Private Limited for a substantial portion of its imports may expose it to risks if this supplier faces operational challenges. However, the inclusion of additional suppliers provides a level of diversification, which can help buffer against potential disruptions.

The company imports a diverse range of finished pharmaceutical formulations, indicating a broad product portfolio. This diversity can enhance supply chain resilience by reducing the impact of disruptions in any single product line. Additionally, the company's established relationships with multiple suppliers suggest a proactive approach to managing supply chain risks.

Importing Pharmaceuticals into Peru — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Peru

1Regulatory Authority & Framework

In Peru, the primary regulatory authority overseeing pharmaceutical imports is the Dirección General de Medicamentos, Insumos y Drogas (DIGEMID), which operates under the Ministry of Health. DIGEMID is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Peruvian market.

Key legislation governing pharmaceutical imports includes the Ley General de Salud (General Health Law) and the Reglamento de Insumos y Medicamentos (Regulation of Supplies and Medicines). These regulations establish the requirements for importing, registering, and distributing pharmaceutical products in Peru. The marketing authorization pathway for Indian generics involves obtaining registration from DIGEMID, which includes submitting comprehensive documentation on product composition, manufacturing processes, and clinical data to demonstrate bioequivalence.

2Import Licensing & GMP

Import licensing requirements in Peru stipulate that all pharmaceutical products must be registered with DIGEMID before being imported and marketed. This process involves providing detailed information about the product, including its composition, manufacturing site, and intended use.

Peru recognizes Good Manufacturing Practice (GMP) certificates from reputable international bodies, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Manufacturers from India seeking to export to Peru should ensure their facilities are certified by these organizations to meet Peruvian regulatory standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Peru.

Pharmaceutical Distoloza S.a. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Pharmaceutical Distoloza S.A. focuses on importing oncology medications, specifically vincristine and vinblastine, which are essential in cancer treatment regimens. The company's import data indicates a concentration in the oncology therapeutic category, with these two products accounting for the majority of its imports from India. This strategic focus aligns with the growing demand for cancer treatments in Peru, driven by increasing cancer incidence rates and the need for effective therapies.

2Sourcing Profile

Pharmaceutical Distoloza S.A. employs a sourcing strategy that emphasizes importing generic oncology medications from India. The company's preference for finished pharmaceutical formulations, such as tablets and injections, suggests a focus on ready-to-use products that can be directly distributed to healthcare providers. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a favorable sourcing destination for these products.

3Market Positioning

Based on its product mix, Pharmaceutical Distoloza S.A. serves the hospital and wholesale distribution segments of the Peruvian pharmaceutical market. By supplying essential oncology medications to hospitals and healthcare providers, the company plays a critical role in ensuring the availability of life-saving treatments for cancer patients.

Seller's Guide — How to Become a Supplier to Pharmaceutical Distoloza S.a.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Pharmaceutical Distoloza S.A., particularly in the oncology therapeutic area. The company's current sourcing pattern indicates a reliance on a limited number of suppliers, suggesting potential gaps that new entrants could fill. To capitalize on this opportunity, Indian exporters should offer high-quality products, competitive pricing, and reliable delivery schedules. Additionally, demonstrating compliance with international quality standards and obtaining necessary certifications can enhance the appeal to Pharmaceutical Distoloza S.A.

2Requirements & Qualifications

Indian exporters seeking to supply Pharmaceutical Distoloza S.A. and the Peruvian market must ensure their products are registered with DIGEMID and comply with Peruvian regulatory standards. Manufacturers should possess GMP certifications from recognized international bodies, such as WHO or PIC/S, to meet import requirements. Additionally, products must adhere to Peruvian labeling requirements, including information in Spanish and compliance with serialization mandates.

TransData Nexus Research · Industry procurement practices

Frequently Asked Questions — Pharmaceutical Distoloza S.a.

What products does Pharmaceutical Distoloza S.a. import from India?

Pharmaceutical Distoloza S.a. imports 2 pharmaceutical products across 1 categories. Top imports: Vincristine ($26.8K), Vinblastine ($11.2K).

Who supplies pharmaceuticals to Pharmaceutical Distoloza S.a. from India?

Pharmaceutical Distoloza S.a. sources from 5 verified Indian suppliers. The primary supplier is United Biotech Private Limited (73.6% of imports, $260.0K).

What is Pharmaceutical Distoloza S.a.'s total pharmaceutical import value?

Pharmaceutical Distoloza S.a.'s total pharmaceutical import value from India is $38.0K, based on 6 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Pharmaceutical Distoloza S.a. focus on?

Pharmaceutical Distoloza S.a. imports across 1 categories. The largest: Oncology (100.0%).

Get Full Pharmaceutical Distoloza S.a. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.